e-therapeutics PLC (LON:ETX) chief executive Ray Barlow said he and his research staff were “thrilled” to be working with a “top-five” pharma company on a neurodegenerative diseases project.
The 12-month tie-up with the unnamed drug giant will see ETX’s network-driven drug discovery approach used to identify new disease pathways and small molecules that could be crucial in treating conditions such as Parkinson's, Alzheimer's and Huntington's.
Compounds resulting for e-therapeutics' work will be tested in-house.
“This deal will allow us to directly showcase our network-driven drug discovery technologies to [the pharma company] and the work has the potential to generate new therapeutic assets to add to our existing portfolio,” said CEO Barlow.
“We continue to work on a number of different types of external collaborations and look forward to sharing further news during the remainder of the year."
Neurodegeneration happens when there is progressive loss of structure or function of neurons and can lead to a number of debilitating diseases.
There are currently over one billion people globally affected by these conditions such as Parkinson’s or Alzheimers.